There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
The antiepileptic drug ezogabine (EZG; US adopted name for retigabine [the international
nonproprietary name]) reduces neuronal excitability by enhancing potassium channel
activity. EZG has been approved as adjunctive treatment for adults with partial-onset
seizures.